Deutsche Bank Adjusts Price Target on Elevance Health to $467 From $565
Elevance Health Is Maintained at Overweight by Morgan Stanley
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $549
Morgan Stanley Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $551
Elevance Health Analyst Ratings
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $501
Barclays Remains a Buy on Elevance Health (ELV)
Elevance Health Is Maintained at Buy by TD Cowen
Leerink Partners Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $515
Jefferies Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $529
Jefferies Adjusts Price Target on Elevance Health to $529 From $600, Maintains Buy Rating
TD Cowen Initiates Elevance Health(ELV.US) With Buy Rating, Announces Target Price $484
Elevance Health: Maintaining Buy Rating Amid EPS Growth and Medicaid Challenges
A Quick Look at Today's Ratings for Elevance Health(ELV.US), With a Forecast Between $520 to $622
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
Elevance Health Price Target Cut to $478.00/Share From $585.00 by RBC Capital
A Quick Look at Today's Ratings for Elevance Health(ELV.US), With a Forecast Between $520 to $625
Elevance Health Is Maintained at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on Elevance Health, Lowers Price Target to $485
Elevance Health Analyst Ratings